
Samantha Du, Zai Lab CEO
China's Zai Lab spins 2 more licensing deals, including a sudden dive into neuroscience
China cancer specialist Zai Lab has made its name in-licensing Western drugs and using its deep knowledge of the East Asian market to churn out results. The biotech has now signed two more licensing deals for a trio of drugs, including a very sudden jump into the neuroscience space.
First, Zai Lab inked a deal Tuesday with Karuna Therapeutics for rights in mainland China, Hong Kong, Macau and Taiwan to KarXT, an investigational M1/M4-preferring muscarinic agonist being tested to treat a variety of psychiatric conditions.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters